CLASS II Device recall · Reported 27 Feb 2013 · FDA Enforcement Report

Neuropath 5Fx100 Guiding Cath ST Product recalled by Codman & Shurtleff

Codman & Shurtleff is recalling Neuropath 5Fx100 Guiding Cath ST Product, distributed nationwide in the US. The recall was initiated on 11 Jan 2013 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll unexpired lots
Quantity recalled46 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0858-2013
FDA event ID
64158
Recalling firm
Codman & Shurtleff, Raynham, MA
Classification
Class II
Status
Terminated
Recall initiated
11 Jan 2013
FDA classified
20 Feb 2013
Reported
27 Feb 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

11 Jan 2013Recall initiated by company
20 Feb 2013Classified by FDA+40 days
27 Feb 2013Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Sterility of device may be compromised due to lack of package integrity

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

NEUROPATH 5Fx100 GUIDING CATH ST Product Code: GST51000000 Intended for use in the coronary, peripheral, and neurovasculature for intravascular introduction of interventional/diagnostic devices

Where it was distributed

Worldwide Distribution - USA (nationwide) and Internationally to Austria, Belgium, Canada, Chile, Costa, Rica, Czech Republic, Denmark, France, Germany, Great Britian/UK, Ireland, Italy, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, Slovakia, Spain, and Switzerland.

Nationwide

Questions about this recall

Is Neuropath 5Fx100 Guiding Cath ST Product recalled?

Yes. Codman & Shurtleff recalled Neuropath 5Fx100 Guiding Cath ST Product on 11 Jan 2013. The recall is Class II and its status is Terminated. Recall number Z-0858-2013.

Why was it recalled?

Sterility of device may be compromised due to lack of package integrity

Which lots are affected?

All unexpired lots

Where was it sold?

Worldwide Distribution - USA (nationwide) and Internationally to Austria, Belgium, Canada, Chile, Costa, Rica, Czech Republic, Denmark, France, Germany, Great Britian/UK, Ireland, Italy, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, Slovakia, Spain, and Switzerland.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Codman & Shurtleff

All 59

Other Heart & Vascular Devices recalls

All 6,190